Open Access Article
International Journal of Clinical Research. 2025; 9: (2) ; 37-39 ; DOI: 10.12208/j.ijcr.20250068.
Evaluation of the efficacy of iblitt in paroxysmal atrial fibrillation in patients with coronary heart disease angina
伊布利特对冠心病心绞痛患者阵发性房颤的疗效评价
作者:
赵娟 *,
张苒青,
肖威娜,
徐丽,
王丽娟,
孔德新,
王超,
张巍
哈尔滨市第四医院 黑龙江哈尔滨
*通讯作者:
赵娟,单位:哈尔滨市第四医院 黑龙江哈尔滨;
发布时间: 2025-02-12 总浏览量: 78
PDF 全文下载
引用本文
摘要
目的 评价伊布利特对合并冠心病心绞痛的房颤患者的安全性和有效性。方法 选取2023年1月至2024年8月本院收治的诊断明确为心房颤动同时伴有冠心病心绞痛患者66例。将入选患者随机对照分为两组,各33例,两组患者在常规给予冠心病常规药物治疗基础上:对照组给予胺碘酮治疗;观察组给予伊布利特治疗,比较两组合并冠心病心绞痛的心房颤动患者平均心律转复时间、转复成功率、治疗1h后心电图QRS波时限、心率及QTc间期指标、心功能指标、不良反应发生情况等指标。结果 对照组及观察组治疗后心房颤动较治疗前均好转。观察组平均心律转复时间短于对照组,观察组较对照组患者转复成功率更高,有统计学意义(P<0.05)。治疗前、治疗1h后心电图指标(QRS波时限、心率及QTc间期)存在差异,且观察组优于对照组,具有统计学意义(P<0.05)。治疗后,观察组患者心功能指标优于对照组,差异有统计学意义(P<0.05)。在两组患者不良反应上未见统计学差异(P>0.05)。结论 伊布利特对合并冠心病心绞痛的房颤患者有良好的安全性和有效性,可有效促进心室功能重构,缩短转复时间,提高转复率,临床应用价值较高。
关键词: 伊布利特;冠心病心绞痛;阵发性房颤;胺碘酮;转复
Abstract
Objective To evaluate the safety and efficacy of iibuit in patients with coronary angina. Methods 66 patients from January 2023 to August 2024. The selected patients were divided into two groups: 33 patients each, on the basis of conventional drug therapy for coronary heart disease: the control group, the mean of patients with atrial fibrillation rotation time, success rate, ECG QRS time limit, heart rate and QTc interval index, cardiac function index, and adverse reactions. Results The control group and the observation group were better than before treatment. The mean cardioversion time in the observation group was shorter than that in the control group, and the success rate of cardioversion was higher than that in the observation group, which was statistically significant (P <0.05). The ECG indexes (QRS time limit, heart rate and QTc interval) were different before and 1h after treatment, and the observation group was better than the control group, being statistically significant (P <0.05). After treatment, the observation group was better than the control group (P <0.05). No statistical differences in adverse reactions between the two groups (P> 0.05). Conclusion Ibulit has good safety and effectiveness in atrial fibrillation patients with coronary heart disease and angina pectoris, which can effectively promote ventricular functional remodeling, shorten the turning time, improve the recurrence rate, and has high clinical application value.
Key words: Iblit; Coronary heart disease; Angina pectoris; Paroxysmal atrial fibrillation; Amiodarone; And cardioversion
参考文献 References
[1] 杜娟.胺碘酮与阿托伐他汀联合治疗阵发性心房颤动的疗效分析 [J].内蒙古中医药,2014,33(12):32-33.
[2] 沈斌,潘程婕.伊布利特与电复律用于心房颤动射频消融术中复律的临床效果对比[J].生命科学仪器,2024,22(03): 121-124.
[3] 李中兰,杜洋,李文佳,等.影响伊布利特转复心房颤动成功率的相关因素分析[J].中国循证心血管医学杂志,2024, 16(03):292-295.
[4] 王贵方,樊梅,叶佳辉.伊布利特转复房颤的效果及不良反应分析[J].云南医药,2023,44(06):65-67.
[5] 李中兰,李妍,张艳芹,等.心房率联合左心房内径对伊布利特转复心房颤动成功率预测价值[J].社区医学杂志,2023, 21(19):1016-1021.
[6] 李水泉,陈彦刚.普罗帕酮联合伊布利特治疗持续性心房颤动的效果[J].临床合理用药,2023,16(22):35-39.
[7] 赵晶晶,宋卫锋.伊布利特联合射频消融术治疗老年房颤的临床分析[J].航空航天医学杂志,2022,33(11):1305-1308.
[8] 郑远彪,葛建军,凌飞.伊布利特联合阿托伐他汀对冠状动脉搭桥围术期房颤的预防效果[J].药物评价研究,2022, 45(07):1376-1381.
[9] 刘金明,荣奥运,郝杰,等.伊布利特注射液用于持续性心房颤动射频消融术患者的临床研究[J].中国临床药理学杂志,2022,38(07):623-626.
[10] 刘翰.冠脉造影证实的冠心病稳定型心绞痛患者相关危险因素与其中医证型关系研究[D].湖北中医药大学,2022.
引用本文
赵娟, 张苒青, 肖威娜, 徐丽, 王丽娟, 孔德新, 王超, 张巍, 伊布利特对冠心病心绞痛患者阵发性房颤的疗效评价[J]. 国际临床研究杂志, 2025; 9: (2) : 37-39.